Key Highlights

  • Third-quarter 2026 loss per share was USD 1.05, against an estimate of USD 1.06.
  • Nine-month net loss was USD 190.0 million, with an accumulated Deficit of USD 1.7 billion.
  • Net cash used in Operating Activities was USD 130.1 million for nine months.
  • The ALTO study of KSI-501 in diabetic macular edema began enrolling patients.

Kodiak Sciences (NASDAQ:KOD) reported third-quarter 2026 loss per share of USD 1.05, against an estimate of USD 1.06. The clinical-stage biopharmaceutical company, which reports no product revenue, is developing therapies for retinal diseases, including Zenkuda, KSI-501 and KSI-101.

The filing states that the company has incurred net losses in each reporting period since inception, including a net loss of USD 190.0 million for the nine months ended September 30, 2026. It reports an accumulated deficit of USD 1.7 billion and says it does not project Revenue from product sales for several years, if at all.

Program Expenses

Zenkuda program expenses decreased USD 4.6 million and USD 11.4 million for the three and nine months ended September 30, 2026, which the filing attributes to lower Manufacturing expenses and lower clinical trial costs after the company completed its GLOW2 study of Zenkuda in diabetic retinopathy during the first quarter of 2026.

KSI-501 program expenses increased USD 6.3 million and USD 21.7 million for the three and nine months, due to increased manufacturing expenses as the company ramps up KSI-501 production and increased costs related to the ALTO study of KSI-501 in diabetic macular edema, which began enrolling patients during the third quarter of 2026. KSI-101 program expenses increased USD 9.1 million and USD 26.0 million, primarily due to costs from the PEAK and PINNACLE studies of KSI-101 in macular edema secondary to inflammation, along with increased manufacturing expenses.

General and Administrative Expenses

General and administrative expenses decreased USD 3.1 million in the third quarter, primarily due to a one-time USD 1.9 million non-cash gain recognized upon the termination of one of its Palo Alto, California building leases. In exchange, the company received an option to Lease a separate building on the same campus with certain lease incentives, exercisable through March 1, 2027.

For the nine months, general and administrative expenses decreased USD 9.3 million, including a USD 5.0 million decrease in stock-based compensation expense, as the company is no longer recognizing expense for older, higher-value stock awards that fully vested, and the same USD 1.9 million lease termination gain. During the three and nine months ended September 30, 2025, the company recognized USD 1.8 million and USD 4.2 million of sublease income.

Cash and Capital

Net cash used in operating activities was USD 130.1 million for the nine months, against USD 96.6 million a year earlier. Net cash provided by financing activities was USD 9,963 thousand, against USD 1,057 thousand. Cash, cash equivalents and restricted cash decreased by USD 123,423 thousand to USD 92,623 thousand at September 30, 2026, composed of cash and cash equivalents of USD 88,678 thousand and restricted cash of USD 3,945 thousand.

Common share equivalents excluded from diluted net loss per share because they were antidilutive were 22,432,029, including 22,266,668 outstanding stock options, 139,269 unvested restricted stock units and 26,092 employee stock purchase plan shares.

The filing describes Zenkuda studies including DAYBREAK in wet age-related macular degeneration, where it reports that Zenkuda met the primary endpoint with a p-value of 0.0007 and that 54% of patients were on six-month dosing. It also describes the GLOW1 and GLOW2 studies in diabetic retinopathy and the BEACON study in retinal vein occlusion, in which Zenkuda-treated patients were dosed at eight-week intervals in the first six months, against four-week intervals for aflibercept.